Blog

Diagnosed with a benign pituitary tumor and Cushing's disease, Maple shares the story of her treatment at Pacific Neuroscience Institute.

The Pacific Neuroscience Institute’s state-of-the-art Neurodiagnostic Treatment Suite is complete and providing infusion therapies for a variety of neurological conditions including Multiple Sclerosis (MS) and pituitary disorders such as Pituitary Adenomas. Launched in April 2021, the facility represents another convenience for our patients where they...

The Castle Connolly Top Doctor rigorous selection process is entirely merit-based. For 25 years, Castle Connolly’s mission has been to help people find the best healthcare by connecting patients with best-in-class healthcare providers. They provide an unbiased directory of healthcare providers. Through their extensive research...

This year, seven of Pacific Neuroscience Institute Medical Group’s physicians were included in Los Angeles Magazine’s April 2021 roster of “L.A.’s Top Doctors.” The results were based on a Los Angeles Magazine survey that asked physicians throughout Los Angeles County to identify the doctors they considered to be...

Now twenty-one years in remission from a pituitary adenoma tumor, Sharmyn McGraw, patient advocate, author, artist, and so much more, talks about the pivotal role of Cushing’s disease in her life. From dyslexia to writer and everything in between. Dealing with a life threatening disease,...

Although our medical community continues to strain under the burden of COVID-19, there has been hope, determination and progress. Neurological diseases do not stop and neither have we at Pacific Neuroscience Institute.

New Studies Blue Earth Diagnostics FLC-219: (PDF): An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy (PURSUE) (NCT04410367) Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience ( PDF ): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma ( NCT03463265 ) Orbus Therapeutics ( PDF ): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...